What is HC Wainwright’s Estimate for COYA Q1 Earnings?

Coya Therapeutics, Inc. (NASDAQ:COYA) – Stock analysts at HC Wainwright issued their Q1 2027 earnings estimates for Coya Therapeutics in a note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.46) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.66) EPS.

Several other analysts have also issued reports on the company. Chardan Capital restated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Monday, March 16th. D. Boral Capital reiterated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Monday, March 16th. Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Trading Down 1.7%

Coya Therapeutics stock opened at $4.15 on Tuesday. The business’s 50 day simple moving average is $4.67 and its 200 day simple moving average is $5.48. Coya Therapeutics has a 12 month low of $3.94 and a 12 month high of $7.75. The company has a market cap of $97.36 million, a price-to-earnings ratio of -3.27 and a beta of 0.23.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The company had revenue of $3.96 million for the quarter, compared to analysts’ expectations of $1.93 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.

Institutional Trading of Coya Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in COYA. Alyeska Investment Group L.P. purchased a new stake in Coya Therapeutics during the 4th quarter worth about $4,640,000. AWM Investment Company Inc. bought a new stake in shares of Coya Therapeutics during the fourth quarter valued at about $4,205,000. CM Management LLC increased its position in shares of Coya Therapeutics by 16.7% during the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock valued at $2,030,000 after buying an additional 50,000 shares during the period. Private Management Group Inc. purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth about $1,626,000. Finally, Marshall Wace LLP boosted its position in shares of Coya Therapeutics by 438.8% in the fourth quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after acquiring an additional 183,533 shares during the period. 39.75% of the stock is currently owned by institutional investors.

Key Headlines Impacting Coya Therapeutics

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a high $18.00 price target, and its analyst published FY2027 and quarterly EPS forecasts that anticipate continued investment in the pipeline — this bullish research likely supports investor interest in COYA’s long‑term upside. TipRanks: H.C. Wainwright reiterates Buy
• Neutral Sentiment: Multiple reports show a “large increase” in short interest for March, but the published short-interest totals are zero (and days-to-cover ratios are 0.0), indicating the short-interest data is anomalous/likely erroneous — not a clear driver of price action today.
• Negative Sentiment: Recent quarterly results (reported March 16) showed an EPS miss (reported -$0.34 vs. consensus -$0.08) and continued negative margins and ROE, which keep near-term fundamentals pressured and can blunt enthusiasm from bullish analyst notes.
• Negative Sentiment: Technical and trading context is unfavorable: the stock is below its 50‑day ($4.68) and 200‑day ($5.50) moving averages and near its 52‑week low, and intraday volume is below average — factors that can contribute to downward price pressure despite positive coverage.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.